Zoono's share price slumps after covid serves mixed results

Zoono's share price slumps after covid serves mixed results
A Transport for London worker sprays anti viral solution Zoono-71 inside a tube train north London in May 2020.
Denise McNabb
Covid-19 is turning out to be a double-edged sword for ASX-listed New Zealand antimicrobials company, Zoono Group. Its hand sanitiser sales had benefited from the virus, but chief executive Paul Hyslop said demand for the company’s surface sanitising spray has been hampered by lockdowns leaving offices empty and delaying the need for disinfection protection.“While the company has overall undoubtedly benefited from the impact of the covid-19 pandemic, in many respects the opposite has been the case in the review period in that t...

More Markets

Trump’s tariffs: where things stand
Markets

Trump’s tariffs: where things stand

The basics of the US president’s far-reaching protectionist agenda.

Synlait confident it has enough milk for next two seasons
Primary Sector

Synlait confident it has enough milk for next two seasons

Farmers had until Monday to withdraw their cease notices.

NZ goods to face 10% tariff to access US market
Economy

NZ goods to face 10% tariff to access US market

NZ dollar remains steady after announcement.